Upstream Bio (UPB) Cash from Investing Activities (2023 - 2026)
Upstream Bio (UPB) posted quarterly Cash from Investing Activities of $42.4 million for Q1 2026, up 119.87% year-over-year from $19.3 million in Q1 2025, and down 28.06% quarter-over-quarter from $58.9 million in Q4 2025.
Upstream Bio (UPB) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Upstream Bio's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $42.4 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 119.87% year-over-year to $42.4 million; the TTM figure through Mar 2026 stood at $162.3 million (up 156.61% YoY), while the FY2025 annual figure was -$93.5 million, down 57.15% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $42.4 million, down from $58.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $58.9 million in Q4 2025, with the low at -$213.4 million in Q1 2025.
- The 4-year median for Cash from Investing Activities is $13.3 million (2024), against an average of -$11.6 million.
- Peak annual rise in Cash from Investing Activities reached 3319.87% in 2025, while the deepest fall reached 1640.43% in 2025.
- Upstream Bio's Cash from Investing Activities stood at -$5.2 million in 2023, then surged by 899.47% to $41.9 million in 2024, then jumped by 40.65% to $58.9 million in 2025, then retreated by 28.06% to $42.4 million in 2026.
- Business Quant data shows UPB's Cash from Investing Activities at $42.4 million in Q1 2026, $58.9 million in Q4 2025, and $48.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.76 Mn |
| Jun 30, 2026 | 15.76 Mn |
| Mar 31, 2026 | 42.40 Mn |
| Mar 31, 2026 | 42.40 Mn |
| Dec 31, 2025 | 58.94 Mn |
| Dec 31, 2025 | 58.94 Mn |
| Sep 30, 2025 | 48.19 Mn |
| Sep 30, 2025 | 48.19 Mn |
| Jun 30, 2025 | 12.77 Mn |
| Jun 30, 2025 | 12.77 Mn |
| Mar 31, 2025 | -213.38 Mn |
| Mar 31, 2025 | -213.38 Mn |
| Dec 31, 2024 | 41.91 Mn |
| Dec 31, 2024 | 41.91 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | -116.65 Mn |
| Jun 30, 2024 | -116.65 Mn |
| Mar 31, 2024 | 13.85 Mn |
| Mar 31, 2024 | 13.85 Mn |